Neuren Media and Analyst Coverage, page-1260

Holding onto good businesses can make you very wealthy during a cycle. But holding onto the best businesses can help you weather more than a few cycles - decades, even. These 'best' businesses are what Bridgewater Associates call the "market champions". We talked about this in-depth earlier this week with the help of Datt Capital's Emanuel Datt, Justin Teo of Fidelity International, and Luke Laretive of Seneca Financial Solutions.


Teo nominates Neuren Pharmaceuticals as one company that may have what it takes to go the distance. Not only does it possess the traits of a market champion, he sees similarities in this stock compared to another biotech that Fidelity has backed (to much great success) - Telix Pharmaceuticals.

"Neuren Pharmaceuticals (Neuren) is a biotech that develops treatments for rare neurological disorders. The company’s first commercial product, DAYBUE, is the only treatment approved by the US Food and Drug Administration for patients with Rett syndrome, a disorder that causes the progressive loss of motor and language skills."

"Neuren and its distribution partner Acadia Pharmaceuticals (Acadia) launched DAYBUE in 2023 and Acadia has already achieved over US$250 million of sales in the US, with Neuren
earning royalties on these sales. DAYBUE sales are likely to extend into markets outside the
US once regulatory approvals are achieved."

"Neuren’s next asset, NNZ-2591, is in Phase 2 development and is targeting four different syndromes - Phelan-McDermid, Angelman, Pitt Hopkins and Prader-Willi. The combined addressable market of these syndromes is more than 3x larger than Rett, so if Neuren successfully commercialises them, this should drive a significant valuation increase and help Neuren become a market champion," he said.